Connect with us

Asia Pacific & Australia

Article: Sri Lanka’s woes with cannabis legalisation

Published

on


Himal….

Some propose legalising marijuana production to ease Sri Lanka’s economic crisis. Yet, any move to legalise marijuana cultivation in Sri Lanka will have to overcome a long history of prohibition, social stigma and criminalisation

As Sri Lanka struggles with its worst economic crisis since its Independence, policymakers are increasingly focusing on diversifying the country’s export industries to bring in much-needed foreign exchange, to purchase essentials such as fuel and medicines. Within this context, presenting the budget for the year 2023, President Ranil Wickremesinghe announced the appointment of an expert committee to examine the possibilities of producing cannabis – locally referred to as kansa or ganja – for export purposes.

This echoes Sri Lanka’s state minister of tourism, Diana Gamage, who remains a strong advocate for legalisation and claims it will help the economy. She has earlier promised to bring in investments worth USD 2 billion for the cannabis plantation sector.

The state minister of indigenous medicines, Sisira Jayakody, in an interview stated that the expert committee has made progress and that the final draft of the legal amendments required to make cannabis available for ayurvedic exports has already been sent to the attorney general’s department. “Following the recommendations from the Attorney General, we hope to send it to the Cabinet of Ministers for approval. Once Parliament also approves, we can start this work,” Jayakody said. He further said that although both local and foreign investors had expressed their interest in cannabis cultivation in Sri Lanka, the government was yet to begin lengthier discussions with them due to legal barriers.

Sri Lanka remains strict on the use of cannabis for recreational and medicinal purposes, despite many tourist hotspots being popular havens for the consumption of cannabis and related products. While cannabis has been legalised in many countries, its cultivation and export remain controversial due to its history as an illegal drug and its potential for misuse. Further, exporting cannabis from Sri Lanka would require navigating a complex legal landscape and establishing proper regulatory frameworks to ensure compliance with both domestic and international laws. Additionally, the cultural attitudes towards drugs in Sri Lanka may pose challenges for the commercial cultivation of cannabis.  Its association with illegal drugs will also make gaining acceptance for commercial cultivation difficult. Moreover, establishing a “profitable” cannabis industry in Sri Lanka will require significant investment in infrastructure, research and development, and regulatory frameworks. This includes setting up proper growing and processing facilities, implementing quality-control measures and developing a robust supply chain to ensure that products meet international standards., It is essential to examine these questions alongside the economic viability of exporting cannabis from Sri Lanka thoroughly.

A 300-year ban

Cannabis use for medicinal purposes has been recorded in Sri Lankan history for centuries. Some claim that early writings on cannabis date back as far as 341 CE, when King Buddhadasa of Anuradhapura wrote about it in his pharmacopoeia, Sarartha Sangrahaya. In fact, Wickremesinghe, in his address to Parliament, used the Sanskrit term for cannabis, “thriloka wijayapathra” meaning “victory over three realms”.

The head of the department of crop science at the University of Ruhuna, K K I U Arunakumara, states that there is written evidence about the historical use of cannabis in local medicine: “The kings write books about local medicine. Those books state that kansa is a very valuable drug.” Negative attitudes towards cannabis use in Sri Lanka can be traced back to the country’s colonial past. The Dutch introduced the ban on cannabis use in Sri Lanka in the 17th century, which the British colonial administration subsequently renewed. “After the Dutch, the British government also banned it,”Arunakumara states “That amendment by the British is still there in the law – no Sri Lankan government has banned it. Kansa was banned because it was used. It was used because it was cultivated in the country. We can conclude then that historically, kansa was cultivated, and reasonably believe that it was at a level where it could have been exported.”

Exporting cannabis from Sri Lanka would require navigating a complex legal landscape and establishing proper regulatory frameworks to ensure compliance with both domestic and international laws.

“There are four names: kansa, ganja, cannabis and marijuana. When we call it kansa, there is a pleasantness, but that is not there when we call it ganja. People have forgotten how cannabis became ganja in Sri Lanka. There is a cultural context for this,” said Arunakumara, emphasising the need to change cultural attitudes towards cannabis by highlighting its history.

“We need to tell people the truth. Only if there is successful acceptance from society can we eventually explore its uses in the local market too,” he added.

Cannabis use in Sri Lanka has been stigmatised and continues to be seen as a social and moral issue. The National Dangerous Drugs Control Board (NDDCB) has reported that, in 2021, cannabis was the most commonly used illicit drug in Sri Lanka, with an estimated 301,898 users. The NDDCB states that as of 2020, nearly two percent of the population above age 14 used cannabis as a drug in the last 14 years.

According to the NDDCB, in 2021, the Police Narcotics Bureau recorded that possession of cannabis and Kerala cannabis led to the second and third highest percentages of drug-related arrests, after those linked to heroin. In fact, of the total 110,031 drug-related arrests in 2021, 30 percent were for cannabis possession. The grouping of cannabis with other, more dangerous drugs, such as heroin, coupled with blanket criminalisation, contributes significantly to the stigma surrounding cannabis.

Read full article

Sri Lanka’s woes with cannabis legalisation



Source link

Continue Reading

Asia Pacific & Australia

A shortage of prescribed medical cannabis supply has led to Australian patients being left stranded, according to the Legalise Cannabis Queensland Party (LCQP).

Published

on

By


Just about sums up what wrong with medical cannabis supply in Australia if the LCQP assertions are true.

There are a million reasons why this is happening and msot of it is due to bad govt policy and greed on the part of some suppliers who know that they aren’t just supplying to a “medical” market.

 

 

Source: https://lismoreapp.com.au/NewsStory/australian-medical-cannabis-patients-face-ongoing-product-shortages/677783b6bcd792002e21893f

A shortage of prescribed medical cannabis supply has led to Australian patients being left stranded, according to the Legalise Cannabis Queensland Party (LCQP).

The disruption to vital medication for those who rely on it for chronic conditions, pain and other medical issues is doing patient harm, says patient advocate and Secretary of the LCQP Suzette Luyken.

“This isn’t just an inconvenience; it is doing harm to patients,” said Suzette Luyken, patient advocate and Secretary of the Legalise Cannabis Queensland Party.

“Before Christmas, supply chains were closing for extended periods, and those with psychiatric disabilities were badly affected. Depressions deepen over this season, and the results can be devastating for those who suffer from PTSD and depression. Imagine if this were insulin or heart medication—it would be a national scandal.”

Medical cannabis was legalised in Australia in 2016, offering hope to patients with conditions often resistant to conventional therapies. However, the reality has been far less promising. Supply chain disruptions, inadequate stock and poor planning have left pharmacies unable to fill prescriptions, forcing patients to endure the consequences.

 

“For many patients, the fallout has been severe. The interruption of care has left many struggling to manage their conditions effectively. Patients must endure debilitating symptoms; go back on to heavy-duty pharmaceuticals, or seek out product from the black market.”

The crisis has sparked urgent calls for action from both government agencies and the corporate cannabis industry. Key demands from patients and advocacy groups include:

1.          Improved supply chain transparency and planning.

2.          Emergency stock reserves to prevent shortages.

3.          Greater accountability from manufacturers and distributors.

“Australia has excelled in many areas of healthcare, but when it comes to medical cannabis, we are letting our patients down,” said Suzette Luyken. “It’s time for regulators, manufacturers, and distributors to address these issues with the urgency they deserve.”

 

Southside Chempro owner Kyle Wood told the Lismore App he doesn’t think there is an inherent problem with the supply of medical cannabis.

“Medical cannabis has a conservative shelf life, so when it is imported into Australia, it has about six months to be distributed and used.

“The pharmaceutical companies have to anticipate what the supply will be in advance. With a conservative shelf life, this can leave them losing a lot of money, which they don’t want to do.

“It’s fine for the big-name brands who don’t have supply problems, but the smaller, boutique growers can have problems with the next grow crop. The bio-equivalence will never be the same, meaning the flower varies from crop to crop.”

The Australian medical cannabis industry is still too young to cover domestic supply, so overseas companies are needed to fill the gap.

 

Federal Government legislation also prohibits substituting between products, which causes supply chain issues.

Kyle said that supply chains can get caught up, and there can be a shortage for a month or two.



Source link

Continue Reading

Asia Pacific & Australia

Cannabiz Weekly Report (Australia) Headlines Suggests A Rather Sickly Sector – Maybe They Need Some Medical Cannabis!

Published

on

By


Firms owed $1.7m by OneLife Labs

OneLife Labs owes more than A$1.7 million to creditors, including $365,000 to Colombian producer Clever Leaves, as potential buyers continue to explore the acquisition of its manufacturing facility.

Health House parent hits financial wall as Melodiol enters administration

Health House parent Melodiol Global Health has entered voluntary administration, the third medicinal cannabis company to hit the financial wall in the space of six weeks.

Epsilon sets ‘roadmap’ but issues remain as firm seeks ASX return

Epsilon Healthcare has “re-established its foundation” and has a “clear roadmap for sustainable profitability”, its chairman has said.

Releaf’s new owners explore plan to bring franchisees back

The newly-formed joint venture which acquired Releaf Group assets has approached former franchisees as it looks to rebuild the network and bring disillusioned patients back into the fold.

Melodiol facing creditor and loan debts of $17m, report reveals

Troubled Melodiol Global Health has racked up A$17 million worth of debt, an initial administrator’s report has revealed, as efforts continue to sell its distribution arm, Health House.

Homepage



Source link

Continue Reading

Asia Pacific & Australia

Paper – Australia: NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development.

Published

on

By


An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS.

A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.

Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10-90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients.

The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.

© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media